Hope Tribune

Massive Opportunity For SANUWAVE After Celularity’s UltraMIST® Acquisition; Four Investor Presentations Set For September

 Breaking News
  • No posts were found

Massive Opportunity For SANUWAVE After Celularity’s UltraMIST® Acquisition; Four Investor Presentations Set For September

August 28
09:30 2020

The value created from SANUWAVE’S (OTCMKTS: SNWV) acquisition of Celularity’s UltraMIST® assets may be under-the-radar for now. But, four planned investor presentations during September will deliver the message that the markets are missing- the acquisition created a transformative moment for SANUWAVE.

The asset acquisition immediately brings more than $15 million in accretive revenues to the company’s yearly run-rate. Additionally, the company secured premium licensing terms for two important biologics, Biovance and Interfyl, creating a comprehensive wound-care treatment platform that can effectively treat patients from discovery to closure. And to drive new sales nationally, SANUWAVE will benefit from a trained sales force of roughly 100 people with the industry knowledge to maximize the combined strength of the platform’s enhanced and cutting edge technology.

The complementary nature of UltraMIST® and SANUWAVE’s flagship device, dermaPACE®, will be the driver for success. Most importantly, patients and providers can quickly benefit from this FDA-approved best-in-class wound-care treatment platform with SANUWAVE seizing the cross-selling opportunities from roughly 1000 customer accounts with only 15 that overlap.

Notably, UltraMIST® alone generated more than $15M in revenues and $4M in adjusted EBITDA in 2019.

Video Link: https://www.youtube.com/embed/a7NzXi6gFqw

Busy Presentation Schedule In September

SANUWAVE will be telling its story in September. Kevin A. Richardson II, CEO of SANUWAVE, is scheduled to present at four major virtual investor conferences next month. Each offers significant opportunities for investors to digest the true value behinds this game-changing acquisition for SANUWAVE. It may also tighten the valuation disconnect between current stock price levels that are neglecting the enormous boost to revenues and EBITDA earnings. 

 

The September 2020 presentation schedule includes:

 

The LD Micro 500

Dates: September 1 – 4, 2020 

Company presentation: Wednesday, September 2, 2020, at 8:40 am ET

Format: Corporate presentation and One-on-One Investor Meetings

 

The Global Chinese Financial Forum-Investing in Innovation

Dates: September 10, 2020

Company presentation: Thursday, September 10, 2020, at 11:15 am PST (2:15 pm ET)

Format: Corporate presentation and One-on-One Investor Meetings

 

HC Wainwright 22nd Annual Global Investment Conference 

Dates: September 15-16, 2020

Company Presentation: Wednesday, September 16, 2020, at 4:00 pm ET

Format: Corporate presentation and One-on-One Investor Meetings

 

Lake Street Capital Markets 4th Annual Best Ideas Growth Conference (Big 4) 

Dates: September 17, 2020

Format: One-on-One Investor Meetings

 

Each presentation will be webcast live and is accessible through the Events section of SANUWAVE Health’s website at www.SANUWAVE.com, where they will also be archived.

SANUWAVE’s message is expected to resonate with its institutional and retail investor audience. Further, these conferences allow the company to highlight the significant growth opportunities inherent in its recent acquisition of Celularity’s UltraMIST® assets. It also allows them to show the competitive differences, and advantages, compared to industry giants like Johnson & Johnson (NYSE: JNJ) and Medtronic (NYSE: MDT). Medtronic recently reported revenues of more than $550 million from its diabetes group, a number that demonstrates just a portion of the market opportunities for SANUWAVE.

Most notably, the acquisition provides SANUWAVE with a robust product offering in the advanced wound care market. Moreover, this transformative event provides SANUWAVE with a platform of scale, immediately brings substantial recurring revenue, and gives SANUWAVE an end-to-end advanced wound care product portfolio that addresses the entire care pathway that is compelling to patients, providers, and payers.

As September unfolds, the value opportunity at current levels may shrink, especially after investors digest just how transformative this acquisition is for the company.

 

Disclaimers: Blue Hawk Media, LLC is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. The information made available by Blue Hawk Media, LLC is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Blue Hawk Media, LLC be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Blue Hawk Media, LLC, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. This video and its release is to syndicated outlets has been produced through the engagement of a third party, SANUWAVE, Inc., who has hired Blue Hawk Media, LLC to prepare a research and video report for SANUWAVE. The company has compensated Blue Hawk Media, LLC three-thousand-five-hundred dollars to prepare original content, video production , and syndication services.

Media Contact
Company Name: Blue Hawk Media, LLC
Contact Person: Kenny Ellis
Email: Send Email
Country: United States
Website: https://www.soulstringmedia.com